Cefepime

Cefepime (BMY-28142) is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime induces neurotoxicity[1][2][3][4].

Product Specifications

CAS Number

[88040-23-7]

Product Name Alternative

BMY-28142

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Antibiotic; Bacterial; Penicillin-binding protein (PBP)

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/cefepime.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1

Molecular Formula

C19H24N6O5S2

Molecular Weight

480.56

Precautions

H302, H312, H332

References & Citations

[1]Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7 (5) :338-48. |[2]Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47 (3) :471-505.|[3]Payne LE, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21 (1) :276. doi: 10.1186/s13054-017-1856-1. |[4]Máthé A, et al. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006 Jul;40 (3) :296-300.